



Ref. SNMCH/PO/2026/22

Date 10-01-2026

## Pharmacovigilance Committee

Pharmacovigilance Committee of Shree Narayan Medical Institute and Hospital, Saharsa, has been constituted as per regulations of Medical Council of India, 2010, are as follows: -

S. No.	Name, Designation, Department	Designation
1.	Dr. Krishna Kumar Lal, Principal	Chairperson
2.	Dr. Kumar Devashish, Asst. Prof. Dept. of Pharmacology	Coordinator
3.	Dr. Ravindra Kumar Gupta, Assoc. Prof., Dept. of Gen. Surgery.	Member Secretary
4	Dr. Prakash Tomar Prof., Dept. of Pharmacology	Member
5.	Dr. Meenakshi Singh, Assoc. Prof., Dept. of Obstetrics & Gynaecology	Member
6.	Dr. Vijay Kumar Jha, Assoc. Prof., Dept. of Pathology	Member
7.	Dr. Nitish Kumar, Asst. Prof., Dept. of Paediatrics	Member
8.	Dr. Rajanish Chaurasiya, Assistant Professor, Dept. of Physiology	Member
9.	Dr. Sandeep Bharadwaj, Asst. Prof., Dept. of General Medicine	Member

**Pharmacovigilance** is the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other drug-related problems. Pharmacovigilance cell functions under the **Department of Pharmacology, Shree Narayan Medical Institute & Hospital, Mahavir Nagar, Bherdhari, Saharsa – 852201 (Bihar)** The Pharmacovigilance Program of India (PvPI) was launched with a broad objective to safe guard the health of 1.27 billion people of India. Adverse Drug Reaction (ADRs) are reported from all over the country to NCC-PvPI, which also work in collaboration with the global ADR monitoring center (WHO-UMC). Sweden to contribute in the global ADRs data base. NCC-PvPI monitors the ADRs among Indian Population and helps the Regulatory Authority of India (CDSCO) In taking decision for safe use of medicines.

Scope and Objectives of PvPI and ADR monitoring program:

- To create a nation-wide system for patient safety reporting
- To identify and analyze new signal from the reported cases
- To analyze the benefit – risk ration of marketed medicines
- To generate evidence based information on safety of medicines
- To support regulatory agencies in the decision-making process on use of medications
- To communicate the safety information on use of medicines to various stakeholders to minimize the risk
- To emerge as a national center of excellence for pharmacovigilance activities
- To collaborate with other national centers for the exchange of information and data management
- To provide training and consultancy support to other national Pharmacovigilance centers across globe
- To promote rational use of medicine

**Helpline Number: 1800 180 3024**



**The mission of PvPI** is to safeguard the health of the Indian population by ensuring that the benefit of use of medicine outweighs the risks associated with its use. Since there exist considerable social and economic consequences of adverse drug reactions and the positive benefit/cost ratio of implementing appropriate risk management-there is a need to engage healthcare professionals and the public at large, in a well-structured program to build synergies for monitoring adverse drug reactions in the country.

**The Purpose of the PvPI** is to collate data, analyze it and use the inferences to recommend informed regulatory interventions, besides communicating risks to healthcare professionals and the public. The broadened patient safety scope of pharmacovigilance includes the detection of medicines of substandard quality as well as prescribing, dispensing and administration errors. Counterfeiting, antimicrobial resistance, and the need for real time surveillance in mass vaccinations are other pharmacovigilance challenges which need to be addressed. The vision of PvPI is to improve patient safety and welfare in Indian population by monitoring drug safety and thereby reducing the risk associated with use of medicines. The ultimate safety decisions on medicines may need considerations of comparative benefit/risk evaluations between products for similar indications, so the complexity is great.

Principal  
Principal  
SNMIH, Saharsa  
Saharsa (Bihar)-852201  
10/01/2026